The incremental cost of providing adequate hemodialysis

Dialysis and Transplantation

Volumn 32, Issue 9, 2003, Pages 526-534

  Sehgal, Ashwini R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; ARTIFICIAL KIDNEY; BLOOD VESSEL GRAFT; CATHETER; COST BENEFIT ANALYSIS; FEMALE; FISTULA; HEALTH CARE COST; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROFIT; QUANTITATIVE ANALYSIS; REIMBURSEMENT;

EID: 0042323089     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. New Engl J Med 2002; 347:2010-2019.
2. Health Care Financing Administration. 2000 Annual Report. ESRD Clinical Performance Measures Project. Baltimore, MD, 2000.
3. Sehgal AR, Dor A, Tsai AC. The morbidity and cost implications of inadequate hemodialysis. Am J Kidney Dis 2001;37:1223-1231.
4. Sehgal AR, Leon JB, Siminoff LA, Singer ME, Bunosky LM, Cebul RD. Improving the quality of hemodialysis treatment: A community-based randomized controlled trial to overcome patient-specific barriers. J Am Med Assoc 2002;287:1961-1967.
5. Medicare Payment Advisory Commission. Report to the Congress: Medicare Payment Policy (March 2001). Washington, DC.
6. Ray N. Medicare Payment Advisory Commission, Washington, DC. Personal Communication. July 2, 2001.
7. Meyer KB, Kassirer JP. Squeezing more cost and care out of dialysis: Our patients would pay the price. Am J Med 2002;112:232-234.
8. Iglehart JK. The End-Stage Renal Disease Program. New Engl J Med 1993;328:366-371.
9. McClellan WM, Frankenfield DL, Frederick PR, Flanders WD, Alfaro-Correa A, Rocco M, Helgerson SD. Can dialysis therapy be improved? A report from the ESRD Core Indicators Project. Am J Kidney Dis 1999; 34:1075-1082.
10. Rettig RA, Levinsky NG. Kidney Failure and the Federal Government. Washington, DC: National Academy Press, 1991.
11. Held PJ, Garcia JR, Pauly MV, Cahn MA. Price of dialysis, unit staffing, and length of dialysis treatment. Am J Kidney Dis 1990; 15:441-450.
12. Parker TF. Will changing the dialysis prescription have a significant impact on patient mortality and the financial status of the facility? Contemp Dial Nephrol 1997; 18(6):17-19.
13. Hirth R, Held P, Orzol S, Dor A. Practice patterns, case mix, Medicare payment policy, and dialysis facility costs. Health Serv Res 1999; 33:1567-1592.
14. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J Am Soc Nephrol 1993; 4:1205-1213.
15. U.S. Renal Data System. USRDS 2000 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000.
16. Frankenfield DL, Rocco MV, Frederick PR, Pugh J, McClellan WM, Owen WF. Racial/ethnic analysis of selected intermediate outcomes for hemodialysis patients: Results from the 1997 ESRD Core Indicators Project. Am J Kidney Dis 1999; 34:721-730.
17. Leon JB, Sehgal AR. Identifying patients at risk for hemodialysis underprescription. Am J Nephrol 2001; 21:200-207.
18. Lowrie EG, Chertow GM, Lew NL, Lazarus JM, Owen WF. The urea [clearance x dialysis time] product (Kt) as an outcome-based measure of hemodialysis dose. Kidney Int 1999; 56:729-737.
19. Owen WF, Chertow GM, Lazarus JM, Lowrie EG. Dose of hemodialysis and survival: Differences by race and sex. J Am Med Assoc 1998; 280:1764-1768.
20. Leggat JE, Orzol SM, Hulbert-Shearon TE, Golper TA, Jones CA, Held PJ, Port FK. Noncompliance in hemodialysis: Predictors and survival analysis. Am J Kidney Dis 1998; 32:139-145.
21. Chertow G. Leveling the "paying" field in end-stage renal disease. Am J Med 2000; 108:666-668.
22. Farley DO, Carter GM, Kallich JD, Lucas TW, Spritzer KL. Modified capitation and treatment incentives for end-stage renal disease. Health Care Financing Rev 1996; 17:129-142.
23. Hidai H. Need for an incentive-based reimbursement policy toward quality care for dialysis patient management. Kidney Int 2000; 58:363-373.
24. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23:661-669.